I don’t think prime editing needs to wait. —Fyodor Urnov, University of California, Berkeley While working in Liu’s lab at the Broad Institute, Anzalone achieved promising gene editing results in ...

Prime Medicine’s ‘search-and-replace’ genome editing technology – initially identified by gene-editing pioneers David Liu and Andrew Anzalone at the Broad Institute – has already been ...

RJ has a Master’s degree in Clinical Neurosciences from the University of Cambridge. View Full Profile. Learn about our Editorial Policies. In their 2019 paper, Liu’s team used prime editing to alter ...

Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

The company was set up by gene-editing pioneers David Liu, who co-founded Editas Medicine and Beam Therapeutics, and Andrew Anzalone of the Broad Institute of MIT and Harvard University.